Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2010 Mar 16;33(3):132–138. doi: 10.1002/clc.20714

QRS Duration Is Associated With Atrial Fibrillation in Patients With Left Ventricular Dysfunction

Mikhael F El‐Chami 1,✉, Candace Brancato 2, Jonathan Langberg 1, David B Delurgio 1, Heather Bush 2,3, Lynne Brosius 2, Angel R Leon 1
PMCID: PMC6653136  PMID: 20235216

Abstract

Background:

QRSduration (QRSd) is associated with higher mortality and morbidity in patients with left ventricular (LV) dysfunction. The association between QRSd and atrial fibrillation (AF) has not been studied in this patient population.

Objectives:

To investigate the association between QRSd and AF in patients with LV dysfunction.

Methods:

Data were obtained from the National Registry to Advance Heart Health (ADVANCENT) registry, a prospective multicenter registry of patients with left ventricular ejection fraction (LVEF) ≤ 40%. A total of 25 268 patients from 106 centers in the United States, were enrolled between June 2003 and November 2004. Demographic and clinical characteristics of patients were collected from interviews and medical records.

Results:

Mean age was 66.3±13 years, 71.5% were males, and 81.9% were white. A total of 14 452 (57.8%) patients had a QRSd < 120 ms, 5304 (21.2%) had a QRSd between 120 and 150 ms, and 5269 (21%) had a QRSd > 150 ms. Atrial fibrillation occurred in 20.9%, 27.5%, and 35.5% of patients in the QRS groups, respectively (P < 0.0001). After adjusting for potential AF risk factors (age, gender, race, body mass index, hypertension, diabetes, renal failure, cancer, lung disease, New York Heart Association [NYHA] class, ejection fraction, etiology of cardiomyopathy) and the use of angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, β‐blockers, and lipid lowering drugs, QRS duration remained independently associated with AF (odds ratio: 1.20, 95% confidence interval: 1.14–1.25).

Conclusion:

In this large cohort of patients, QRSd was strongly associated with AF and therefore may predict the occurrence of this arrhythmia in patients with LV dysfunction. This association persisted after adjusting for disease severity, comorbid conditions, and the use of medications known to be protective against AF. Copyright © 2010 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (188.9 KB).

References

  • 1. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325(5): 293a–302. [DOI] [PubMed] [Google Scholar]
  • 2. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 32(3): 695–703. [DOI] [PubMed] [Google Scholar]
  • 3. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316(23): 1429–1435. [DOI] [PubMed] [Google Scholar]
  • 4. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF‐STAT). The Department of Veterans Affairs CHF‐STAT Investigators. Circulation 1998; 98(23): 2574–2579. [DOI] [PubMed] [Google Scholar]
  • 5. Stevenson WG, Stevenson LW. Atrial fibrillation in heart failure. N Engl J Med 1999; 341(12): 910–911. [DOI] [PubMed] [Google Scholar]
  • 6. Stevenson WG, Stevenson LW. Atrial fibrillation and heart failure—five more years. N Engl J Med 2004; 351(23): 2437–2440. [DOI] [PubMed] [Google Scholar]
  • 7. Torp‐Pedersen C, Moller M, Bloch‐Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341(12): 857–865. [DOI] [PubMed] [Google Scholar]
  • 8. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285(26): 1441–1446. [DOI] [PubMed] [Google Scholar]
  • 9. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population‐based study. Eur Heart J 1999; 20(6): 421–428. [DOI] [PubMed] [Google Scholar]
  • 10. Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev 2000; 5(2): 167–173. [DOI] [PubMed] [Google Scholar]
  • 11. Aneja A, Tang WH, Bansilal S, et al. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 2008; 121(9): 748–757. [DOI] [PubMed] [Google Scholar]
  • 12. Cohen‐Solal A, Beauvais F, Logeart D. Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J Card Fail 2008; 14(7): 615–625. [DOI] [PubMed] [Google Scholar]
  • 13. Bradley TD, Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. Lancet 2009; 373(9657): 82–93. [DOI] [PubMed] [Google Scholar]
  • 14. Kannel WB, Benjamin EJ. Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin 2009; 27(1): 13–24, vii. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Schoonderwoerd BA, Smit MD, Pen L, Van Gelder IC. New risk factors for atrial fibrillation: causes of “not‐so‐lone atrial fibrillation.” Europace 2008; 10(6): 668–673. [DOI] [PubMed] [Google Scholar]
  • 16. Stevenson IH, Teichtahl H, Cunnington D, et al. Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function. Eur Heart J 2008; 29(13): 1662–1669. [DOI] [PubMed] [Google Scholar]
  • 17. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999; 100(1): 87–95. [DOI] [PubMed] [Google Scholar]
  • 18. Phang RS, Isserman SM, Karia D, et al. Echocardiographic evidence of left atrial abnormality in young patients with lone paroxysmal atrial fibrillation. Am J Cardiol 2004; 94(4): 511–513. [DOI] [PubMed] [Google Scholar]
  • 19. Corell P, Gustafsson F, Schou M, et al. Prevalence and prognostic significance of atrial fibrillation in outpatients with heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail 2007; 9(3): 258–265. [DOI] [PubMed] [Google Scholar]
  • 20. Parkash R, Maisel WH, Toca FM, et al. Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved. Am Heart J 2005; 150(4): 701–706. [DOI] [PubMed] [Google Scholar]
  • 21. Kashani A, Barold SS. Significance of QRS complex duration in patients with heart failure. J Am Coll Cardiol 2005; 46(12): 2183–2192. [DOI] [PubMed] [Google Scholar]
  • 22. Wang NC, Maggioni AP, Konstam MA, et al. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA 2008; 299(22): 2656–2666. [DOI] [PubMed] [Google Scholar]
  • 23. Yerra L, Anavekar N, Skali H, et al. Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. Heart Rhythm 2006; 3(3): 313–316. [DOI] [PubMed] [Google Scholar]
  • 24. De Winter O, Van de Veire N, Van Heuverswijn F, et al. Relationship between QRS duration, left ventricular volumes and prevalence of nonviability in patients with coronary artery disease and severe left ventricular dysfunction. Eur J Heart Fail 2006; 8(3): 275–277. [DOI] [PubMed] [Google Scholar]
  • 25. Murkofsky RL, Dangas G, Diamond JA, et al. A prolonged QRS duration on surface electrocardiogram is a specific indicator of left ventricular dysfunction [see comment]. J Am Coll Cardiol 1998; 32(2): 476–482. [DOI] [PubMed] [Google Scholar]
  • 26. Hanna IR, Heeke B, Bush H, Lipid‐lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006; 3(8): 881–816. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Hanna IR, Heeke B, Bush H, The relationship between stature and the prevalence of atrial fibrillation in patients with left ventricular dysfunction. J Am Coll Cardiol 2006; 47(8): 1683–1688. [DOI] [PubMed] [Google Scholar]
  • 28. Galizio NO, Pesce R, Valero E, Which patients with congestive heart failure may benefit from biventricular pacing? Pacing Clin Electrophysiol 2003; 26(1 pt 2): 158–161. [DOI] [PubMed] [Google Scholar]
  • 29. Grimm W, Sharkova J, Funck R, et al. How many patients with dilated cardiomyopathy may potentially benefit from cardiac resynchronization therapy? Pacing Clin Electrophysiol 2003; 26(1 pt 2): 155–157. [DOI] [PubMed] [Google Scholar]
  • 30. Kalra PR, Sharma R, Shamim W, et al. Clinical characteristics and survival of patients with chronic heart failure and prolonged QRS duration. Int J Cardiol 2002; 86(2–3): 225–231. [DOI] [PubMed] [Google Scholar]
  • 31. Kearney MT, Zaman A, Eckberg DL, et al. Cardiac size, autonomic function, and 5‐year follow‐up of chronic heart failure patients with severe prolongation of ventricular activation. J Card Fail 2003; 9(2): 93–99. [DOI] [PubMed] [Google Scholar]
  • 32. Shenkman HJ, Pampati V, Khandelwal AK, et al. Congestive heart failure and QRS duration: establishing prognosis study. Chest 2002; 122(2): 528–534. [DOI] [PubMed] [Google Scholar]
  • 33. Sandhu R, Bahler RC. Prevalence of QRS prolongation in a community hospital cohort of patients with heart failure and its relation to left ventricular systolic dysfunction. Am J Cardiol 2004; 93(2): 244–246. [DOI] [PubMed] [Google Scholar]
  • 34. Baldasseroni S, Opasich C, Gorini M, et al. Left bundle‐branch block is associated with increased 1‐year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 2002; 143(3): 398–405. [DOI] [PubMed] [Google Scholar]
  • 35. Stellbrink C, Auricchio A, Diem B, et al. Potential benefit of biventricular pacing in patients with congestive heart failure and ventricular tachyarrhythmia. Am J Cardiol 1999; 83(5B): 143D–150D. [DOI] [PubMed] [Google Scholar]
  • 36. Fonarow GC, Heywood JT, Heidenreich PA, et al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2007; 153(6): 1021–1028. [DOI] [PubMed] [Google Scholar]
  • 37. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Titcolor European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006; 8(9): 651–745. [DOI] [PubMed] [Google Scholar]
  • 38. Rienstra M, Van Veldhuisen DJ, Hagens VE, et al. Gender‐related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol 2005; 46(7): 1298–1306. [DOI] [PubMed] [Google Scholar]
  • 39. Ruo B, Capra AM, Jensvold NG, Go AS. Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study. J Am Coll Cardiol 2004; 43(3): 429–435. [DOI] [PubMed] [Google Scholar]
  • 40. Hanrahan JP, Grogan DR, Baumgartner RA, et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long‐acting β2‐agonists arformoterol and salmeterol. Medicine (Baltimore) 2008; 87(6): 319–328. [DOI] [PubMed] [Google Scholar]
  • 41. Iguchi Y, Kimura K, Kobayashi K, et al. Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol 2008; 102(8): 1056–1059. [DOI] [PubMed] [Google Scholar]
  • 42. Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and obesity—results of a meta‐analysis. Am Heart J 2008; 155(2): 310–315. [DOI] [PubMed] [Google Scholar]
  • 43. Adam O, Neuberger HR, Bohm M, et al. Prevention of atrial fibrillation with 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors. Circulation 2008; 118(12): 1285–1293. [DOI] [PubMed] [Google Scholar]
  • 44. Belluzzi F, Sernesi L, Preti P, et al. Prevention of recurrent lone atrial fibrillation by the angiotensin‐II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009; 53(1): 24–29. [DOI] [PubMed] [Google Scholar]
  • 45. Bourassa MG. Angiotensin II inhibition and prevention of atrial fibrillation and stroke. J Am Coll Cardiol 2005; 45(5): 720–721. [DOI] [PubMed] [Google Scholar]
  • 46. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post‐Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005; 45(4): 525–530. [DOI] [PubMed] [Google Scholar]
  • 47. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96(7): 2455–2461. [DOI] [PubMed] [Google Scholar]
  • 48. Mazzoleni A, Curtin ME, Wolff R, et al. On the relationship between heart weights, fibrosis, and QRS duration. J Electrocardiol 1975; 8(3): 233–236. [DOI] [PubMed] [Google Scholar]
  • 49. Yamada T, Fukunami M, Ohmori M, et al. New approach to the estimation of the extent of myocardial fibrosis in patients with dilated cardiomyopathy: use of signal‐averaged electrocardiography. Am Heart J 1993; 126(3 pt 1): 626–631. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES